Vipera lebetina venom contains two disintegrins inhibiting laminin-binding beta1 integrins.
To explain the myotoxic effects of snake venoms, we searched for inhibitors of alpha7beta1 integrin, the major laminin-binding integrin in skeletal muscle. We discovered two inhibitors in the venom of Vipera lebetina. One of them, lebein-1 (known as lebein), has already been proposed to be a disintegrin because of its RGD-containing primary sequence. The other, lebein-2, is a novel protein that also interacts firmly with alpha3beta1, alpha6beta1, and alpha7beta1 integrins, but not with the collagen-binding alpha1beta1 and alpha2beta1 integrins. Ligand binding of laminin-recognizing beta1 integrins was efficiently blocked by both lebein-1 and lebein-2. In cell attachment assays, lebein-1 and lebein-2 inhibited myoblast attachment not only to laminin, but also to fibronectin. However, neither lebein-1 nor lebein-2 interacted with alpha7beta1 integrin in an RGD-dependent manner, similar to the interaction of the laminin with alpha7beta1 integrin. Identical divalent cation dependence of integrin binding to laminin and to either of the two inhibitors and their mutually exclusive binding suggest that both lebein-1 and lebein-2 interact with the ligand-binding site of laminin-binding beta1 integrins by mimicking the yet unknown integrin-binding structure of laminins. Like lebein-1, lebein-2 is a soluble heterodimeric disintegrin of low molecular mass. Together with membrane-bound ADAM-2 and ADAM-9, the two inhibitors seem to form a small group of disintegrins that can bind to laminin-binding beta1 integrins. Because of their inhibitory capability both in vitro and in vivo, lebein-1 and lebein-2 may be valuable tools in influencing laminin-induced, integrin-mediated cell functions such as cell anchorage, migration, and mechanical force transduction on laminin-rich basement membranes.
Eble
Johannes A
JA
Institute for Physiological Chemistry, Münster University Hospital, 48149 Münster, Germany. eble@uni-muenster.de
Bruckner
Peter
P
Mayer
Ulrike
U
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D003435:Crotalid Venoms / Q000633:toxicity; D019483:Disintegrins / Q000737:chemistry* / Q000633:toxicity*; D004546:Elapid Venoms / Q000633:toxicity; D005353:Fibronectins / Q000378:metabolism; D066298:In Vitro Techniques; D039201:Integrin alpha3beta1 / Q000187:drug effects / Q000378:metabolism; D019012:Integrin beta1 / Q000187:drug effects* / Q000378:metabolism*; D016023:Integrins / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D007797:Laminin / Q000378:metabolism*; D051379:Mice; D032446:Myoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry; D011485:Protein Binding / Q000187:drug effects; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D014757:Viper Venoms / Q000737:chemistry* / Q000633:toxicity*
D003435:Crotalid Venoms; D019483:Disintegrins; D004546:Elapid Venoms; D005353:Fibronectins; D039201:Integrin alpha3beta1; D019012:Integrin beta1; D016023:Integrins; D007797:Laminin; D009842:Oligopeptides; D011994:Recombinant Proteins; D014757:Viper Venoms; C121346:laminin 1; C428664:lebein; C047981:arginyl-glycyl-aspartic acid; C082908:integrin alpha7beta1